<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01038869</url>
  </required_header>
  <id_info>
    <org_study_id>FIN0901</org_study_id>
    <nct_id>NCT01038869</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Study of Finacea to Treat Acne Vulgaris and Post-Inflammatory Hyperpigmentation (PIH)</brief_title>
  <official_title>Efficacy and Safety of Finacea in the Treatment of Post-Inflammatory Hyperpigmentation and Acne Vulgaris</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Derm Research, PLLC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Derm Research, PLLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Residual post-inflammatory hyperpigmentation (PIH)from acne is disturbing to individuals with
      skin of color. Finacea has been anecdotally known to be beneficial in resolving PIH related
      to acne vulgaris. However, it has not been clinically tested for this purpose. The current
      study will investigate the efficacy and safety of Finacea in the treatment of acne vulgaris
      and PIH.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2009</start_date>
  <completion_date type="Actual">May 2010</completion_date>
  <primary_completion_date type="Actual">April 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Improvement in Acne IGA (Investigator Global Assessment)</measure>
    <time_frame>Baseline to 16 weeks</time_frame>
    <description>IGA Assessments at each visit (baseline and follow up) based on a 6 point scale (0= clear through 5 = very severe). Improvement is defined as at least a 1 point improvement.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Improvement in the IGA of Post Inflammatory Hyperpigmentation(PIH)</measure>
    <time_frame>Baseline to16 weeks</time_frame>
    <description>IGA for PIH assessed on a 7 point scale (0= clear through 6 = severe) with at least a two point improvement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With an Improvement in Post Inflammatory Hyperpigmentation (PIH) % Distribution</measure>
    <time_frame>Baseline to 16 weeks</time_frame>
    <description>The % distribution of PIH, evaluated on a scale of 0 = no PIH through 6 = greater than 50%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Change in Total Lesion Counts</measure>
    <time_frame>Baseline to 16 weeks</time_frame>
    <description>Total lesions including inflammatory lesions (papules, pustules, nodules) and non-inflammatory lesions (open and closed comedones).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerability Assessments as Measured by the Number of Participants With Side Effects</measure>
    <time_frame>16 weeks</time_frame>
    <description>Tolerability parameters assesssed by the presence and degree of peeling, erythema, dryness, oiliness, burning and pruritus</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Acne Vulgaris</condition>
  <condition>Post Inflammatory Hyperpigmentation</condition>
  <arm_group>
    <arm_group_label>Azelaic acid 15% (Finacea)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Open label pilot study, Topical gel to be appiled twice daily for 16 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azelaic acid</intervention_name>
    <description>Apply sparingly to the face twice a day (morning and night). Massage gently into the skin until vanishing. Approximately 0.5g (2.5cm strip) is sufficient for the entire facial area.</description>
    <arm_group_label>Azelaic acid 15% (Finacea)</arm_group_label>
    <other_name>Finacea</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female, at least 12 years of age

          -  Female subjects of childbearing potential must have a negative urine pregnancy test at
             Baseline

          -  Fitzpatrick skin type IV to VI

          -  Acne IGA (Investigator Global Assessment) score of 2 or 3

          -  Inflammatory lesions of 15-60 (with no more than 2 nodules)

          -  Non-inflammatory lesions of 20-100

          -  Post Inflammatory Hyperpigmentation Investigator Global Assessment (PIH IGA) score of
             3,4 or 5

          -  Able to understand the requirements of the study and sign Informed Consent/HIPAA
             forms. Subjects under the legal age of consent must have the written informed consent
             of a parent or legal guardian

        Exclusion Criteria:

          -  Female subjects who are pregnant, breast-feeding or who are of childbearing potential
             and not practicing a reliable method of birth control

          -  Allergy or sensitivity to any component of the test medication

          -  Subjects who have not complied with the wash out periods for prohibited medications

          -  Medical condition that contraindicates participation

          -  Skin disease/disorder that might interfere with the diagnosis of acne vulgaris or PIH

          -  Evidence of recent alcohol or drug abuse

          -  History of poor cooperation, non-compliance or unreliability

          -  Exposure to an investigational drug study within 30 day of Baseline visit
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Leon H. Kircik, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>DermResearch, PLLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>DermResearch, PLLC</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40217</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 23, 2009</study_first_submitted>
  <study_first_submitted_qc>December 23, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 24, 2009</study_first_posted>
  <results_first_submitted>March 26, 2012</results_first_submitted>
  <results_first_submitted_qc>August 24, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 25, 2012</results_first_posted>
  <last_update_submitted>August 24, 2012</last_update_submitted>
  <last_update_submitted_qc>August 24, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 25, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Derm Research, PLLC</investigator_affiliation>
    <investigator_full_name>Leon Kircik, M.D.</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acne Vulgaris</mesh_term>
    <mesh_term>Hyperpigmentation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azelaic acid</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects recruited from private office population.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Finacea</title>
          <description>Open label pilot study. All subjects were given Azelaic acid 15% to be used topically, twice daily.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Finacea</title>
          <description>Open label pilot study</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24" spread="10.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Improvement in Acne IGA (Investigator Global Assessment)</title>
        <description>IGA Assessments at each visit (baseline and follow up) based on a 6 point scale (0= clear through 5 = very severe). Improvement is defined as at least a 1 point improvement.</description>
        <time_frame>Baseline to 16 weeks</time_frame>
        <population>Per protocol</population>
        <group_list>
          <group group_id="O1">
            <title>Azelaic Acid 15% Open Label</title>
            <description>Assessments of IGA</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Improvement in Acne IGA (Investigator Global Assessment)</title>
          <description>IGA Assessments at each visit (baseline and follow up) based on a 6 point scale (0= clear through 5 = very severe). Improvement is defined as at least a 1 point improvement.</description>
          <population>Per protocol</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Improvement in the IGA of Post Inflammatory Hyperpigmentation(PIH)</title>
        <description>IGA for PIH assessed on a 7 point scale (0= clear through 6 = severe) with at least a two point improvement</description>
        <time_frame>Baseline to16 weeks</time_frame>
        <population>per protocol</population>
        <group_list>
          <group group_id="O1">
            <title>Azelaic Acis 15% Open Label</title>
            <description>Assessments of PIH IGA</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Improvement in the IGA of Post Inflammatory Hyperpigmentation(PIH)</title>
          <description>IGA for PIH assessed on a 7 point scale (0= clear through 6 = severe) with at least a two point improvement</description>
          <population>per protocol</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With an Improvement in Post Inflammatory Hyperpigmentation (PIH) % Distribution</title>
        <description>The % distribution of PIH, evaluated on a scale of 0 = no PIH through 6 = greater than 50%</description>
        <time_frame>Baseline to 16 weeks</time_frame>
        <population>per protocol</population>
        <group_list>
          <group group_id="O1">
            <title>Azelaic Acid 15%</title>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With an Improvement in Post Inflammatory Hyperpigmentation (PIH) % Distribution</title>
          <description>The % distribution of PIH, evaluated on a scale of 0 = no PIH through 6 = greater than 50%</description>
          <population>per protocol</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>2 grade improvement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 grade improvement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Change in Total Lesion Counts</title>
        <description>Total lesions including inflammatory lesions (papules, pustules, nodules) and non-inflammatory lesions (open and closed comedones).</description>
        <time_frame>Baseline to 16 weeks</time_frame>
        <population>per protocol</population>
        <group_list>
          <group group_id="O1">
            <title>Azelaic Acid 15%</title>
            <description>lesion counts</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change in Total Lesion Counts</title>
          <description>Total lesions including inflammatory lesions (papules, pustules, nodules) and non-inflammatory lesions (open and closed comedones).</description>
          <population>per protocol</population>
          <units>percentage of total lesion count</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-92.4" spread="10.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tolerability Assessments as Measured by the Number of Participants With Side Effects</title>
        <description>Tolerability parameters assesssed by the presence and degree of peeling, erythema, dryness, oiliness, burning and pruritus</description>
        <time_frame>16 weeks</time_frame>
        <population>per protocol</population>
        <group_list>
          <group group_id="O1">
            <title>Azelaic Acid 15%</title>
            <description>tolerability assessments</description>
          </group>
        </group_list>
        <measure>
          <title>Tolerability Assessments as Measured by the Number of Participants With Side Effects</title>
          <description>Tolerability parameters assesssed by the presence and degree of peeling, erythema, dryness, oiliness, burning and pruritus</description>
          <population>per protocol</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Finacea</title>
          <description>Open label pilot study</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>This is an open-label study with a small number of subjects.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Leon Kircik, M.D.</name_or_title>
      <organization>DermResearch, PLLC</organization>
      <phone>502-451-9000</phone>
      <email>wedoderm@yahoo.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

